Key result
A novel percutaneous approach for septal myectomy is outlined as a potential future minimally invasive technique for reducing outflow tract obstruction in hypertrophic obstructive cardiomyopathy.
Why the study?
To highlight the current landscape of septal mass reduction in drug-refractory HOCM, describe evolving minimally invasive techniques, and outline a possible percutaneous approach with a novel device.
This report outlines the current landscape and future percutaneous approaches for septal mass reduction in patients with hypertrophic obstructive cardiomyopathy.
May offer future minimally invasive HOCM option; leaves open need for prospective validation before any practice consideration.
Hypertrophic obstructive cardiomyopathy (HOCM) affects approximately 1 in 500 people globally. The condition results in hypertrophy of the interventricular septum and thickening of the left ventricular wall. Surgical management to resect the thickened myocardium or septal alcohol ablation are currently considered the mainstay treatment option for HOCM refractory to pharmacological therapy. In this special report we aim to highlight the current landscape of septal mass reduction in HOCM. Next, we describe the evolving discipline of minimally invasive techniques for reducing outflow tract obstruction in patients with HOCM. We further consider future options and outline a possible percutaneous approach for septal myectomy with a novel device.
No takes yet. Share an insight, caveat, or question.
Ojha et al. (2023) conducted a review in Hypertrophic obstructive cardiomyopathy (HOCM). Percutaneous approach for septal myectomy was evaluated. A novel percutaneous approach for septal myectomy is outlined as a potential future minimally invasive technique for reducing outflow tract obstruction in hypertrophic obstructive cardiomyopathy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: